Hans Marcus Bosson
Chief Executive Officer bij QUIAPEG PHARMACEUTICALS HOLDING AB
Profiel
Hans Marcus Bosson is the founder of Resistentia Pharmaceuticals AB, founded in 1998, where he held the title of Chief Executive Officer until 2010.
He was also the founder of QuiaPEG Pharmaceuticals AB, founded in 2012, where he held the title of Chief Executive Officer & Director.
Currently, he is the CEO & Independent Director at Quiapeg Pharmaceuticals Holding AB since 2017.
Previously, he worked as the Chief Executive Officer at Ryda Bruk AB and as a Director at BioArctic AB.
Mr. Bosson has a graduate degree from Stockholm School of Economics and the University of Stockholm.
Actieve functies van Hans Marcus Bosson
| Bedrijven | Functie | Begin |
|---|---|---|
| QUIAPEG PHARMACEUTICALS HOLDING AB | Chief Executive Officer | 01-01-2017 |
Eerdere bekende functies van Hans Marcus Bosson
| Bedrijven | Functie | Einde |
|---|---|---|
Resistentia Pharmaceuticals AB
 Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Founder | 24-06-2010 |
Ryda Bruk AB
 Ryda Bruk AB Miscellaneous Commercial ServicesCommercial Services Part of Beijerinvest AB, Ryda Bruk AB is a consulting services provider. The private company is based in Heby, Sweden. | Chief Executive Officer | - |
QuiaPEG Pharmaceuticals AB
 QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Founder | - |
| BIOARCTIC AB | Director/Board Member | - |
Opleiding van Hans Marcus Bosson
| Stockholm School of Economics | Graduate Degree |
| University of Stockholm | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOARCTIC AB | Health Technology |
| QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Ryda Bruk AB
Ryda Bruk AB Miscellaneous Commercial ServicesCommercial Services Part of Beijerinvest AB, Ryda Bruk AB is a consulting services provider. The private company is based in Heby, Sweden. | Commercial Services |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
